GlassScriptPhysician profile
Sanjeev K Mittal
NPI 1689603102
$8,895.27
in general payments reported to CMS, 2019-2025
33 companies · $1,194 in 2025
The $1,194 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,159 · 2020: $747 · 2021: $1,294 · 2022: $1,972 · 2023: $1,438 · 2024: $1,090 · 2025: $1,194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,442 · Education: $281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,441.50 |
| Education | $281.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,048.56 | 2019-2025 | Jynarque, Voyxact |
| Astrazeneca Pharmaceuticals LP | $974.96 | 2019-2024 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $611.21 | 2019-2025 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $605.60 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $588.08 | 2019-2025 | Velphoro, Velphoro |
| Opko Pharmaceuticals, LLC | $568.19 | 2019-2025 | Rayaldee |
| Aurinia Pharma U.S., INC. | $508.47 | 2021-2025 | Lupkynis |
| Travere Therapeutics, INC. | $413.79 | 2022-2025 | Filspari |
| Mallinckrodt Hospital Products INC. | $349.82 | 2020-2022 | |
| Ani Pharmaceuticals, INC. | $333.58 | 2022-2023 | Purified Cortrophin Gel |
| Akebia Therapeutics INC | $313.97 | 2019-2023 | Auryxia |
| Ultragenyx Pharmaceutical INC. | $311.08 | 2019-2024 | Crysvita |
| Lilly USA, LLC | $301.15 | 2023-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $276.84 | 2023-2025 | |
| Amgen INC. | $275.42 | 2019-2023 | Tavneos, Parsabiv |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $257.34 | 2020-2022 | |
| Ardelyx, INC. | $227.57 | 2023-2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $164.91 | 2022-2025 | Tarpeyo |
| Horizon Therapeutics Plc | $124.55 | 2019-2023 | Krystexxa |
| Ipsen Biopharmaceuticals, INC | $111.37 | 2025 | Bylvay |
| Veloxis Pharmaceuticals, INC. | $95.84 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.34 | 2023-2025 | Jardiance |
| Arbor Pharmaceuticals, INC. | $79.33 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $60.68 | 2019 | |
| Lundbeck LLC | $42.48 | 2019 | |
| Baxter Healthcare | $30.60 | 2022 | |
| Novo Nordisk INC | $28.65 | 2025 | Ozempic |
| Alnylam Pharmaceuticals INC. | $22.68 | 2021 | |
| Genzyme Corporation | $19.31 | 2022 | |
| Shield Therapeutics INC | $17.23 | 2023 | Accrufer |
| Nuwellis, INC. | $16.13 | 2021 | |
| Allergan, INC. | $15.48 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjeev Mittal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.